Physiological basis of contraceptive function of a GSK3α-selective inhibitor, manifested during epididymal sperm maturation
Molecular Human Reproduction · 2026
DOI: 10.1093/molehr/gaag049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Human Reproduction, 2026. Verfasst von Aditi Khamamkar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, Karnataka, India. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3, Epididymis, Sperm Maturation, Spermatozoa. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Biotechnology, Ministry of Science and Technology.
Abstract (Originalsprache)
Glycogen synthase kinase 3 alpha (GSK3α) has emerged as a prospective target to develop male contraceptives. Global or testis-specific loss of GSK3α, but not GSK3β, results in male infertility. Previous studies demonstrated that the GSK3α-selective inhibitor BRD0705 induces reversible infertility in heterozygous mice. Here, we show that BRD0705 induces similar infertility in wild-type male mice. Fertility outcomes remain largely unaltered following superovulation in female mice mated with BRD0705-treated males. Further, no evidence of foetal resorption was observed in these females. Sperm count in treated mice was not altered; however, morphological defects appeared during their passage through the epididymis. The GSK3α inhibitor affected pathways related to the enzyme’s catalytic activity in epididymal sperm. Phosphoproteomic analysis of sperm from inhibitor-treated mice showed that phosphorylation of over 50 proteins involved in motility, metabolism, and fertility, among others, was significantly altered. Among the highly hypophosphorylated proteins, four are likely substrates of GSK3 (viz., AKAP4, NT5C1B, SPATA18, and TRA2B). Analysis of the seminiferous tubules of BRD0705-treated mice showed normal spermatogenesis, suggesting that the drug did not affect developing spermatogenic cells. However, in vitro exposure of post-meiotic germ cells demonstrated their susceptibility to this inhibitor. BRD0705, therefore, shows only a non-genomic effect at the post-translational level. These findings support GSK3α inhibition via BRD0705 as a non-hormonal, on-demand, and reversible male contraceptive strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, Karnataka, India.
- Department of Reproductive Science, Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.
- Centre for the Development of Therapeutics, Broad Institute, Cambridge, MA, USA.
- Department of Biological Sciences, Kent State University, Kent, OH, USA.
ORCID-Profile: Satish Kumar Adiga, Souvik Dey
Förderung
- Department of Biotechnology, Ministry of Science and Technology
Zitieren
APA
Khamamkar, A., Roy, R., Shivakumar, D. A., Choudhari, N., Dutta, R., Weïwer, M., Adiga, S. K., Vijayaraghavan, S., & Dey, S. (2026). Physiological basis of contraceptive function of a GSK3α-selective inhibitor, manifested during epididymal sperm maturation. Molecular Human Reproduction. https://doi.org/10.1093/molehr/gaag049
Vancouver
Khamamkar A, Roy R, Shivakumar DA, Choudhari N, Dutta R, Weïwer M, et al. Physiological basis of contraceptive function of a GSK3α-selective inhibitor, manifested during epididymal sperm maturation. Molecular Human Reproduction. 2026. doi:10.1093/molehr/gaag049
BibTeX
@article{Khamamkar2026,
author = {Khamamkar, Aditi and Roy, Rounak and Shivakumar, Dhanu Anneyplar and Choudhari, Neha and Dutta, Rahul and Weïwer, Michel and Adiga, Satish Kumar and Vijayaraghavan, Srinivasan and Dey, Souvik},
title = {Physiological basis of contraceptive function of a GSK3α-selective inhibitor, manifested during epididymal sperm maturation},
journal = {Molecular Human Reproduction},
year = {2026},
doi = {10.1093/molehr/gaag049}
}
EUVIMED